Following the accreditation of the key institution of "Zhangjiang Science Park", employees are eligible for the benefits of talent settlement policy, mainly in the residence permit settlement and talent introduction program.

(hereinafter referred to as Leadingtac Bio), a company in Zhangjiang Science City announced the completion of a Pre-A round of financing led by Yuan Sheng Venture Capital, with additional investment from long-time shareholder ZJ LEADING VC. This funding round will be used primarily to advance the company's first Protein Degrader pipeline for autoimmune disease treatment to the clinical research stage and to develop follow-on programs and pipelines, including oncology and other autoimmune diseases. With the previous angel round, Leadingtac has raised nearly 100 million RMB in cumulative early-stage financing.

At the end of 2019, a new team, Leadingtac Bio, emerged on the track of targeted protein degradation in Zhangjiang Pharmaceutical Valley, Pudong, Shanghai. This company focuses on the research and development of new small- molecule drugs in autoimmune and oncology diseases. Although it was infant, its founder, Yan Feng, was already one of the pioneers of innovative drug development in China in 2005.